GlassScriptPhysician profile
Edward P Clack
NPI 1659629053
$8,554.04
in general payments reported to CMS, 2019-2025
36 companies · $2,650 in 2025
The $2,650 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.72 · 2021: $379 · 2022: $1,188 · 2023: $2,002 · 2024: $2,321 · 2025: $2,650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,973.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,972.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,407.58 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $1,260.91 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $1,083.50 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $920.98 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $674.56 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $566.40 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Exact Sciences Corporation | $560.40 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $489.89 | 2022-2025 | Repatha, Otezla, Otezla |
| Merck Sharp & Dohme LLC | $343.92 | 2022-2025 | Gardasil 9, Capvaxive, Gardasil |
| Glaxosmithkline, LLC. | $244.97 | 2021-2025 | Trelegy Ellipta, Shingrix, Bexsero |
| Abbott Laboratories | $158.17 | 2023-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $100.61 | 2021-2025 | Trintellix |
| Astellas Pharma US INC | $96.10 | 2024-2025 | Veozah |
| Idorsia Pharmaceuticals US INC | $65.60 | 2022-2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $57.85 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $48.33 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $42.76 | 2022 | |
| Renalytix Ai, INC. | $39.39 | 2022 | |
| Novartis Pharmaceuticals Corporation | $37.50 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $34.79 | 2022-2024 | Eliquis |
| Seqirus USA INC | $30.27 | 2022 | |
| Radius Health, INC. | $29.30 | 2024 | Tymlos |
| Axsome Therapeutics, INC. | $26.25 | 2025 | Symbravo |
| Otsuka America Pharmaceutical, INC. | $24.26 | 2024 | Abilify Maintena, Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.75 | 2025 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.29 | 2025 | Caplyta |
| Lundbeck LLC | $19.61 | 2025 | Rexulti |
| Grifols USA, LLC | $19.43 | 2022 | |
| Janssen Pharmaceuticals, INC | $19.27 | 2022 | |
| Kyowa Kirin, INC. | $18.46 | 2023 | Crysvita |
| Sanofi Pasteur INC. | $17.99 | 2021 | |
| Gilead Sciences, INC. | $16.78 | 2025 | |
| Dexcom, INC. | $15.40 | 2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $14.17 | 2021 | |
| Evoke Pharma, INC. | $12.50 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $11.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Clack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.